Hyperbaric Oxygen Therapy Improved Neovascularisation Following Limb Ischaemia—The Role of ROS Mitigation
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von You-Cheng Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, Department of Surgery, Chi-Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Hyperbaric Oxygenation, Ischemia, Reactive Oxygen Species, Neovascularization, Physiologic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, Chi-Mei Medical Center, Ministry of Science and Technology.
Abstract (Originalsprache)
Hyperbaric oxygen (HBO) therapy has emerged as a potential treatment, shown to enhance blood flow and angiogenesis. However, specific effects and mechanisms of HBO on limb ischaemia responding to a hypoxic environment remain largely unknown. We aimed to investigate the therapeutic potential of HBO in the treatment of limb ischaemia. Following limb ischaemia surgery, we evaluated the angiogenic capacity in wild‐type C57BL/6J mice subjected to HBO treatment (100% oxygen at 3 ATA for 1 h/day for five consecutive days) compared to untreated controls. Notably, through laser Doppler perfusion imaging and CD31 staining mice receiving HBO postlimb ischaemia surgery exhibited significantly enhanced angiogenic capability and reduced ROS expression compared to nontreated counterparts. Additionally, in vitro experiments were conducted to investigate whether HBO could mitigate endothelial cell dysfunction and reactive oxygen species (ROS) production triggered by oxygen–glucose deprivation (OGD). HBO treatment rescued the impaired proliferation, migration and tube formation of endothelial cells following OGD. Mechanistically, HBO upregulated the expression of proangiogenic proteins, including vascular endothelial growth factor (VEGF), haem oxygenase‐1 (HO‐1), hypoxia‐inducible factor 1 (HIF‐1) and nuclear factor erythroid 2–related factor 2 (Nrf2). Collectively, HBO treatment shows promise in augmenting the endogenous angiogenic potential and suppressing ROS levels in limb ischaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Plastic Surgery, Department of Surgery, Chi-Mei Medical Center, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Cardiology, Chi Mei Medical Center, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Department of Hyperbaric Oxygen Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
ORCID-Profile: Wei-Ting Chang
Förderung
- National Health Research Institutes
- Chi-Mei Medical Center
- Ministry of Science and Technology
Zitieren
APA
Lin, Y. C., Shih, J. Y., Lin, Y. W., Niu, K. C., Hong, C. S., Chen, Z. C., Pan, S. C., Chang, T. Y., Kan, W. C., & Chang, W. T. (2024). Hyperbaric Oxygen Therapy Improved Neovascularisation Following Limb Ischaemia—The Role of ROS Mitigation. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70310
Vancouver
Lin YC, Shih JY, Lin YW, Niu KC, Hong CS, Chen ZC, et al. Hyperbaric Oxygen Therapy Improved Neovascularisation Following Limb Ischaemia—The Role of ROS Mitigation. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70310
BibTeX
@article{Lin2024,
author = {Lin, You-Cheng and Shih, Jhih-Yuan and Lin, Yu-Wen and Niu, Ko-Chi and Hong, Chon-Seng and Chen, Zhih-Cherng and Pan, Shin-Chen and Chang, Tzu-Yen and Kan, Wei-Chih and Chang, Wei-Ting},
title = {Hyperbaric Oxygen Therapy Improved Neovascularisation Following Limb Ischaemia—The Role of ROS Mitigation},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70310}
}
EUVIMED